top of page

AI Revolutionizes Antibody Development: Beyond Human Imagination

Imagine a world where revolutionary medical antibodies, far beyond what human scientists could conceive, are crafted with the precision of artificial intelligence. Welcome to the innovative realm of LabGenius, a London-based startup that is harnessing AI to transform the field of antibody engineering.

Gone are the days of ovens and mixers in the old biscuit factory in South London. In their place stand robotic arms, incubators, and DNA sequencing machines, the tools of LabGenius' trade. This company is not in the business of baking sweet treats; it's focused on revolutionizing medical science through an AI-powered approach to crafting antibodies.

Antibodies: Nature's Disease Fighters

In the natural world, antibodies serve as the body's frontline warriors against diseases. These specialized protein strands are shaped to cling to foreign invaders, aiding their elimination from the body. For decades, pharmaceutical companies have been producing synthetic antibodies to combat diseases like cancer and reduce the risk of organ rejection in transplants.

The Challenge of Antibody Design

However, the process of designing these antibodies has been a slow and laborious task for humans. Protein designers have had to sift through an almost infinite array of potential amino acid combinations to find the precise sequences that will fold together correctly. Subsequent experimental testing was required to determine their effectiveness, with the hope that improvements in one aspect of the treatment wouldn't inadvertently worsen others. It's like searching for a needle in a haystack, as LabGenius CEO James Field explains.

LabGenius: An Artificial Intelligence Powered Solution

In 2012, James Field founded LabGenius, seizing the opportunity presented by the decreasing costs of DNA sequencing, computing power, and robotics. The company capitalizes on all three to largely automate the antibody discovery process. At their Bermondsey laboratory, a machine learning algorithm takes the lead in designing antibodies tailored to target specific diseases. Automated robotic systems then take over, growing, testing, and refining these antibodies with minimal human intervention.

Human scientists begin by identifying a search space for potential antibodies to combat a particular disease. They seek proteins capable of distinguishing between healthy and diseased cells, binding to the latter, and enlisting immune cells to complete the task. However, this quest spans a vast and virtually limitless landscape of possibilities. LabGenius addresses this challenge with a machine learning model capable of rapid and effective exploration of this vast space. Human input consists of presenting examples of healthy and diseased cells, allowing the system to navigate the intricacies of antibody design.

The Quest for the Perfect Antibody

The machine learning model sifts through over 700 initial antibody options within a search space of 100,000 potential candidates. These antibodies are then automatically designed, constructed, and tested, with the objective of identifying promising candidates for further investigation. It's akin to selecting the ideal car from a multitude of options, starting with broad criteria and narrowing down the choices.

Testing is a highly automated process, featuring an array of advanced equipment for sample preparation and analysis. Antibodies are grown based on their genetic sequences and subjected to biological assays using samples of the targeted diseased tissue. While humans oversee the process, their role primarily involves moving samples from one machine to another.

A Learning Journey

The experimental data generated is invaluable. It feeds back into the machine learning model, enhancing its understanding of how different antibody designs influence treatment effectiveness. With each cycle, the model refines its ability to balance the exploitation of promising designs with exploration of new territory.

Traditional protein engineering often involves exhaustive fine-tuning of a molecule once it shows some promise. However, this approach can inadvertently lead to unfavorable changes in other crucial attributes. LabGenius challenges this conventional wisdom, exploring the broader landscape of possibilities, and avoiding the trap of endlessly optimizing one solution. It's about finding the right forest instead of fixating on individual trees.

LabGenius is blazing a trail in the field of antibody development, unlocking possibilities beyond human imagination. Through the fusion of artificial intelligence and real-world experimentation, they are rapidly expanding the horizons of what is achievable in the world of medical science.



bottom of page